Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ACP1 | P24666 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426281 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587416 | 0.88 | ACP1 (0.60) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587476 | 0.85 | ADORA1 (0.47) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587503 | 0.84 | CYP1A2 (0.48) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587470 | 0.84 | HRH4 (0.47) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587448 | 0.83 | ADORA1 (0.46) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587506 | 0.83 | ACP1 (0.62) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL22587438 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL29426168 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP3A4CLK4HSD17B10TSHR | |
| SCHEMBL7751195 | 0.82 | ADORA1 (0.67) | CYP1A2CYP3A4CLK4HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127063-B | Pyrimidine five-membered heterocyclic compounds and application thereof as mutant IDH2 inhibitor | 上海仕谱生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-06-30 | — | — | US | disclosed |
| EP-3967691-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-16 | — | — | EP | disclosed |
| EP-3967691-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-16 | — | — | EP | disclosed |
| CN-114127063-A | Pyrimido five-membered heterocyclic compounds and application thereof as mutant IDH2 inhibitor | 上海仕谱生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020215998-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020215998-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | 上海仕谱生物科技有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-111825674-A | Pyrimido five-membered heterocyclic compounds and application thereof as mutant IDH2 inhibitor | 上海仕谱生物科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | IDH2, IDH1, IDH3A | CYP1A2 751/4885CYP3A4 2047/4885CLK4 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.